DUL Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Alnylam Pharmaceuticals Inc

Watchlist Manager

Watchlist

Price: 110.36 EUR Market Closed

Market Cap: €12.8B

A	Alnylam Pharmaceuticals Inc XETRA:DUL	US
	Chorus Ltd NZX:CNU	NZ
J	J.Front Retailing Co Ltd OTC:JFROF	JP
A	Abbott Laboratories F:ABL	US
M	Mitsubishi Heavy Industries Ltd XBER:MIH	JP
C	Campbell Soup Co XMUN:CSC	US
D	Deutsche Boerse AG XHAM:DB1	DE
O	Organizacion Soriana SAB de CV SWB:OSOB	MX
E	Element Fleet Management Corp OTC:ELEEF	CA
L	LSI Industries Inc F:LS2	US
	Shanghai Electric Group Co Ltd OTC:SIELF	CN

Profitability Summary

Alnylam Pharmaceuticals Inc's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

81%

Strong 3Y Average Gross Margin

84%

Declining Gross Margin

81% > 81%

Healthy Operating Margin

17%

Negative 3Y Average Operating Margin

-9%

Operating Margin is Increasing

-73% > 17%

Healthy Net Margin

13%

Negative 3Y Average Net Margin

-16%

Net Margin is Increasing

-86% > 13%

Exceptional Free Cash Flow Margin

15%

Sustainable 3Y Average Free Cash Flow Margin

Free Cash Flow Margin is Increasing

-44% > 15%

Exceptional ROE

97%

Exceptional 3Y Average ROE

Negative 3Y Average ROIC

-10%

ROIC is Increasing

-74% > 40%

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.